Home › Calculator › AKBLF Dividend Calculator 2026
AKBLF DRIP Calculator & Dividend Yield 2026
0.67% YieldHealthcareALK-Abelló A/S · OTC
Price: $36.50 · Annual div: $0.2438/share · Frequency: annual · Payout ratio: 5% · Ex-div: 2026-03-17
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
AKBLF Dividend Yield
AKBLF (ALK-Abelló A/S) has a dividend yield of 0.67%, based on an annual dividend of $0.2438 per share and a price of $36.50. Over the last 12 months it paid $0.2438 per share — a trailing yield of 0.67%. Dividends are paid annual.
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When AKBLF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
AKBLF Dividend History — Last 9 Payments
| Ex-Dividend Date | Payment Date | Amount / Share | TTM Yield | Stock Price |
|---|---|---|---|---|
| 2026-03-17Latest | 2026-03-19 | $0.2438 | 0.68% | $36.10 |
| 2017-03-16 | 2017-03-20 | $0.2500 | — | — |
| 2016-03-11 | — | $0.2500 | — | — |
| 2015-03-13 | — | $0.2500 | — | — |
| 2014-03-13 | — | $0.2500 | — | — |
| 2013-03-13 | — | $0.2500 | — | — |
| 2012-03-28 | — | $0.2500 | — | — |
| 2011-04-04 | — | $0.2500 | — | — |
| 2010-03-29 | — | $0.2500 | — | — |
About ALK-Abelló A/S (AKBLF) — Dividend Analysis 2026
Established in 1923 and headquartered in Hørsholm, Denmark, ALK-Abelló A/S is a global pharmaceutical enterprise specializing in allergy treatment. The company provides a comprehensive range of allergy solutions to markets across Europe, North America, and other international regions. These offerings include immunotherapy products delivered through injections, sublingual drops, and oral tablets, designed to address various allergies such as those caused by house dust mites, grass, tree, ragweed, and Japanese cedar. ALK-Abelló also manufactures adrenaline auto-injectors for the critical management of severe allergic reactions and produces diagnostic tools essential for identifying allergic conditions. Their product portfolio features notable treatments like GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX, all aimed at allergic rhinitis, as well as ACARIZAX, which targets both allergic rhinitis and allergic asthma.
Similar dividend stocks to AKBLF
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full AKBLF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open AKBLF position with:
🌍 AKBLF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold AKBLF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.67% | -2.13% | $67 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.57% | -2.23% | $57 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.54% | -2.26% | $54 / yr |
| 🇬🇧 UK ISA | 0% | 0.67% | -2.13% | $67 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.61% | -2.19% | $61 / yr |
| 🇨🇦 TFSA | 0% | 0.67% | -2.13% | $67 / yr |
| 🇨🇦 CA Taxable | 25% | 0.50% | -2.30% | $50 / yr |
| 🇦🇺 Super (pension) | 15% | 0.57% | -2.23% | $57 / yr |
| 🇦🇺 AU Taxable | 30% | 0.47% | -2.33% | $47 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.49% | -2.31% | $49 / yr |
| 🇫🇷 FR Taxable | 30% | 0.47% | -2.33% | $47 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 AKBLF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.24/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 AKBLF Dividend Payment Schedule
AKBLF pays quarterly — 4 times per year. Ex-div: 2026-03-17.
📊 AKBLF vs Healthcare Benchmarks
How AKBLF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for AKBLF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ AKBLF Insider Activity
No recent SEC filings reported in the last 90 days.Peer Group
Similar companies in the same sectorCompare AKBLF with peers: AKBLF vs CAMRF · AKBLF vs CLCGY · AKBLF vs CSMYF
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the AKBLF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
ALK-Abelló A/S (AKBLF) is currently trading at $36.50, 10% below its 52-week high. The current dividend yield is 0.67% based on an annual payout of $0.2438 per share.
AKBLF (ALK-Abelló A/S) — 0.67% Dividend Yield Analysis
ALK-Abelló A/S (AKBLF) is a healthcare stock currently trading at $36.50 with a dividend yield of 0.67%. It pays an annual dividend of $0.2438 per share. The payout ratio of 5% suggests the dividend is well-covered by earnings.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest AKBLF News
LiveHow investors use the AKBLF dividend calculator
Illustrative examples of common use cases, written by the DividendFlow team — not customer reviews.